HOME > MARKETS > COMPANY NEWS
  COMPANY NEWS
COMPANY
Aurobindo Pharma gets EIR for Telangana unit
May-06-2026

Aurobindo Pharma has received Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Unit-VII, an oral solid dosage manufacturing unit, situated at Special Economic Zone (Pharma), TSIIC, Green Industrial Park, Telangana. The USFDA has classified the said facility as Voluntary Action Indicated (VAI) and this inspection is now closed.

The USFDA had conducted an inspection of the said facility from January 28 to February 10, 2026 and issued a ‘Form 483’ with 09 observations.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.

  RELATED NEWS >>